Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumps.

This review discusses the most recent developments in insulin pump technology. The benefits of the insulin pump to patients with type 1 diabetes are recognized both for its metabolic effectiveness and its positive effects on quality of life. The current pumps are reliable, small and light, and are becoming more and more sophisticated. Nevertheless, there remain practical and psychological constraints for the patient. However, recent patch-pump advances should simplify the technical aspects of pump treatment and enhance patient comfort. Another advance combines the insulin pump with a glucose sensor. Such a combination is logical for optimizing pump use and, to that end, developing an automated or 'closed-loop'system that permits the delivery of subcutaneous insulin adjusted according to measured levels of subcutaneous glucose. Finally, implanted insulin pumps have proven their worth not only because of their simple use, but also for their contribution in the artificial pancreas project. Indeed, the prompt response with intraperitoneal administration of insulin makes it of interest for use in a closed-loop system.

[1]  N. Jeandidier,et al.  French multicentre experience of implantable insulin pumps , 1994, The Lancet.

[2]  E. Renard,et al.  Decreased Severe Hypoglycemia Frequency During Intraperitoneal Insulin Infusion Using Programmable Implantame Pumps , 1996, Diabetes Care.

[3]  V. Lassmann-Vague,et al.  Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumps. , 2003, Diabetes & metabolism.

[4]  F. Pouwer,et al.  Continuous intraperitoneal insulin infusion in patients with ‘brittle’ diabetes: favourable effects on glycaemic control and hospital stay , 2002, Diabetic Medicine.

[5]  N. Jeandidier,et al.  Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients. , 2002, Diabetes care.

[6]  Michael O'Grady,et al.  Continuous glucose monitoring and intensive treatment of type 1 diabetes. , 2008, The New England journal of medicine.

[7]  F. Cameron,et al.  Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. , 2009, Diabetes technology & therapeutics.

[8]  Tadej Battelino,et al.  The SWITCH study (sensing with insulin pump therapy to control HbA(1c)): design and methods of a randomized controlled crossover trial on sensor-augmented insulin pump efficacy in type 1 diabetes suboptimally controlled with pump therapy. , 2011, Diabetes technology & therapeutics.

[9]  D. Raccah,et al.  Insulin Kinetics in Type I Diabetic Patients Treated by Continuous Intraperitoneal Insulin Infusion: Influence of Anti‐insulin Antibodies , 1996, Diabetic Medicine.

[10]  R. Wredling,et al.  Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycaemic response to continuous subcutaneous insulin infusion. , 1991, Diabete & metabolisme.

[11]  J. Pickup.  Semi-closed-loop insulin delivery systems: early experience with low-glucose insulin suspend pumps. , 2011, Diabetes technology & therapeutics.

[12]  G. Slama,et al.  A Cost-Benefit Comparison of Intensive Diabetes Management With Implantable Pumps Versus Multiple Subcutaneous Injections in Patients With Type I Diabetes , 1994, Diabetes Care.

[13]  George Dailey,et al.  Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. , 2010, The New England journal of medicine.

[14]  S. Garg,et al.  Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion Therapy , 2011, Diabetes Care.

[15]  R. Gans,et al.  Health-Related Quality of Life, Treatment Satisfaction, and Costs Associated With Intraperitoneal Versus Subcutaneous Insulin Administration in Type 1 Diabetes , 2010, Diabetes Care.

[16]  Eric Renard,et al.  A recent survey confirms the efficacy and the safety of implanted insulin pumps during long-term use in poorly controlled type 1 diabetes patients. , 2011, Diabetes Technology & Therapeutics.

[17]  E. A. Vaughn,et al.  The kinetics of peritoneal insulin absorption. , 1981, Metabolism: clinical and experimental.

[18]  M. Phillip,et al.  Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes , 2011, Diabetes Care.

[19]  F. Doyle,et al.  Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension , 2010, Diabetes Care.

[20]  D. Kerr,et al.  Pascal's wager: combining continuous glucose monitoring and continuous subcutaneous insulin infusion. , 2010, Diabetes technology & therapeutics.

[21]  M. Charles,et al.  Randomized Comparison of Metabolic Control Achieved by Intraperitoneal Insulin Infusion With Implantable Pumps Versus Intensive Subcutaneous Insulin Therapy in Type I Diabetic Patients , 1992, Diabetes Care.

[22]  Eyal Dassau,et al.  Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring , 2010, Diabetes Care.

[23]  Pharmacokinetics of insulin infused intra-peritoneally via portable pumps. , 1985, Diabete & metabolisme.

[24]  Eric Renard,et al.  Incremental Value of Continuous Glucose Monitoring When Starting Pump Therapy in Patients With Poorly Controlled Type 1 Diabetes , 2009, Diabetes Care.

[25]  T. Jones,et al.  Hypoglycemia: Incidence and Clinical Predictors in a Large Population-Based Sample of Children and Adolescents with IDDM , 1997, Diabetes Care.

[26]  V. Lassmann-Vague,et al.  Local Adverse Events Associated With Long-Term Treatment by Implantable Insulin Pumps: The French EVADIAC Study Group experience , 1998, Diabetes Care.

[27]  D. Raccah,et al.  Immunogenicity of Long-Term Intraperitoneal Insulin Administration With Implantable Programmable Pumps: Metabolic consequences , 1995, Diabetes Care.

[28]  Michaela Miller,et al.  Patch-Pump Technology to Manage Type 2 Diabetes Mellitus: Hurdles to Market Acceptance , 2008, Journal of diabetes science and technology.

[29]  E Renard,et al.  Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. , 2006, Diabetes & metabolism.

[30]  W Kerner,et al.  Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. , 2006, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[31]  B. Guerci,et al.  Quand et comment traiter un patient diabétique par pompe à insuline externe , 2009 .

[32]  R. P. Eaton,et al.  Normalization of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man , 1980, Diabetologia.

[33]  N. Jeandidier,et al.  Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices , 1995, Diabetologia.

[34]  David Kerr,et al.  Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia , 2011, Diabetes Care.

[35]  Howard Zisser,et al.  OmniPod Insulin Management System , 2006, Diabetes Care.

[36]  Christopher G. Parkin,et al.  Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. , 2008, Diabetes technology & therapeutics.

[37]  D. Nathan,et al.  Clinical Trial of Programmable Implantable Insulin Pump For Type I Diabetes , 1992, Diabetes Care.

[38]  E. Renard,et al.  Implantable insulin pumps: infections most likely due to seeding from skin flora determine severe outcomes of pump-pocket seromas. , 2001, Diabetes & metabolism.

[39]  P. Oskarsson,et al.  Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. , 2000, Diabetes & metabolism.

[40]  Henry Anhalt,et al.  Insulin patch pumps: their development and future in closed-loop systems. , 2010, Diabetes technology & therapeutics.

[41]  F. H. Tyler,et al.  Intraperitoneal insulin administration produces a positive portal-systemic blood insulin gradient in unanesthetized, unrestrained swine. , 1982, Metabolism: clinical and experimental.

[42]  Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. , 2011, Diabetes technology & therapeutics.

[43]  E Renard,et al.  Implantable insulin pumps. A position statement about their clinical use. , 2007, Diabetes & metabolism.

[44]  V. Karsten,et al.  Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. , 2001, Diabetes care.

[45]  Eric Renard,et al.  Incremental valúe of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the REALTREND Study , 2010 .

[46]  E. Renard,et al.  Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study , 1995, Diabetes Care.

[47]  F. Ovalle,et al.  Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes , 2009 .

[48]  N. Wong,et al.  Insulin Antibody Responses After Long-Term Intraperitoneal Insulin Administration via Impiantatile Programmable Insulin Delivery Systems , 1994, Diabetes Care.

[49]  W. Lane,et al.  A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[50]  D. B. Keenan,et al.  Accuracy of a New Real-Time Continuous Glucose Monitoring Algorithm , 2010, Journal of diabetes science and technology.

[51]  Matthew Page,et al.  Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. , 2010, The Cochrane database of systematic reviews.

[52]  A. Giobbie-Hurder,et al.  Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group. , 1996, JAMA.

[53]  H. Pitt,et al.  A preliminary trial of the programmable implantable medication system for insulin delivery. , 1989, The New England journal of medicine.

[54]  C. C. Palerm,et al.  Closed-Loop Insulin Delivery Using a Subcutaneous Glucose Sensor and Intraperitoneal Insulin Delivery , 2009, Diabetes Care.

[55]  Bruce Buckingham,et al.  Response to nocturnal alarms using a real-time glucose sensor. , 2005, Diabetes technology & therapeutics.

[56]  H Gin,et al.  Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. , 2003, Diabetes & metabolism.

[57]  Martin Holder,et al.  Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. , 2011, Diabetes technology & therapeutics.

[58]  J. Selam,et al.  Evolution of Diabetes Insulin Delivery Devices , 2010, Journal of diabetes science and technology.